Allelix Pharmaceuticals

Allelix Biopharmaceuticals was a pioneering Canadian biotechnology company focused on the discovery and development of innovative therapeutics in the fields of protein drugs and neuropharmaceuticals. Founded in 1981 and headquartered in Mississauga, Ontario, the company built a robust pipeline featuring lead candidates such as ALX1-11 (recombinant human parathyroid hormone) for osteoporosis and ALX-0600 (teduglutide) for gastrointestinal disorders. Allelix leveraged advanced technologies in molecular biology, medicinal chemistry, and bioinformatics to identify novel disease targets, particularly within the central nervous system. The company established significant partnerships with global pharmaceutical leaders like Eli Lilly, Amgen, and Janssen to advance its research programs. In 1999, Allelix was acquired by NPS Pharmaceuticals in a merger that consolidated their expertise in calcium metabolism and CNS disorders.